歸創通橋-B(02190.HK)中期收入7148.4萬元 同比增長3291.1%
格隆匯8月30日丨歸創通橋-B(02190.HK)公吿,截至2021年6月30日止6個月的中期業績,收入7148.4萬元,同比增長3291.1%;毛利5212.4萬元,同比增長8902.4%;毛利率72.9%。
就公司全面的產品組合而言,公司是中國神經和外周血管介入醫療器械市場的領導者。作為一家以自主研發及製造能力、專有技術平台及經良好往績記錄證實的商業化能力為支撐,並由經驗豐富的管理團隊帶領的綜合醫療器械公司,公司為中國及海外的醫生和患者提供治療及應對神經和外周血管疾病的醫療器械。公司目前的治療領域包括急性缺血性腦卒中(AIS)、顱內動脈瘤、頸動脈狹窄、外周動脈和靜脈疾病及透析相關疾病。
自2021年年初,公司就產品研發已有顯著進展:五款產品獲得國家藥監局批准,如球囊導引導管(BGC)及遠端通路導引導管,兩款產品已取得CE標誌,如顱內血栓抽吸導管。於公吿日期,已合計獲得11項國家藥監局批准及8項CE註冊。十款產品已提交型檢,如顱內血栓抽吸導管及胸主動脈復膜支架系統,三款產品提交國家藥監局批准申請,如顱內動脈瘤栓塞彈簧圈及彈簧圈微導管。九款產品處於臨牀試驗階段,如血流導向裝置、外周靜脈支架系統及血管縫合器。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.